Masimo Corp. (MASI) CEO Joe E. Kiani Sells 999 Shares
Masimo Corp. (NASDAQ:MASI) CEO Joe E. Kiani sold 999 shares of the company’s stock in a transaction that occurred on Monday, September 19th. The stock was sold at an average price of $60.03, for a total value of $59,969.97. Following the completion of the sale, the chief executive officer now owns 120,240 shares of the company’s stock, valued at $7,218,007.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of Masimo Corp. (NASDAQ:MASI) traded up 0.91% during mid-day trading on Wednesday, reaching $59.85. 168,602 shares of the company’s stock traded hands. The firm has a market cap of $2.95 billion, a price-to-earnings ratio of 31.38 and a beta of 0.80. Masimo Corp. has a 52 week low of $33.03 and a 52 week high of $60.46. The company’s 50 day moving average is $58.32 and its 200-day moving average is $49.77.
Masimo Corp. (NASDAQ:MASI) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.16. Masimo Corp. had a net margin of 15.40% and a return on equity of 29.07%. The firm had revenue of $172.64 million for the quarter, compared to analyst estimates of $166.02 million. During the same period in the previous year, the business earned $0.36 EPS. The company’s revenue was up 10.9% compared to the same quarter last year. Equities analysts expect that Masimo Corp. will post $2.02 earnings per share for the current fiscal year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/masimo-corp-masi-ceo-joe-e-kiani-sells-999-shares.html
A number of brokerages have recently commented on MASI. BTIG Research reiterated a “hold” rating on shares of Masimo Corp. in a research report on Friday, August 5th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $55.00 price objective (up previously from $52.00) on shares of Masimo Corp. in a research report on Friday, August 5th. Raymond James Financial Inc. downgraded Masimo Corp. from a “strong-buy” rating to an “outperform” rating in a research report on Wednesday, June 1st. Finally, Wedbush reiterated an “outperform” rating and set a $63.00 price objective (up previously from $60.00) on shares of Masimo Corp. in a research report on Thursday, August 4th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $52.60.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Victory Capital Management Inc. raised its position in Masimo Corp. by 76.9% in the second quarter. Victory Capital Management Inc. now owns 2,148 shares of the company’s stock valued at $113,000 after buying an additional 934 shares in the last quarter. Tower Research Capital LLC TRC purchased a new position in Masimo Corp. during the second quarter valued at $116,000. Quantbot Technologies LP purchased a new position in Masimo Corp. during the second quarter valued at $155,000. Reynders McVeigh Capital Management LLC purchased a new position in Masimo Corp. during the second quarter valued at $203,000. Finally, Janney Capital Management LLC purchased a new position in Masimo Corp. during the second quarter valued at $205,000. Institutional investors own 79.88% of the company’s stock.
Masimo Corp. Company Profile
Masimo Corporation is a medical technology company that develops, manufactures and markets non-invasive patient monitoring products. The Company’s business is measure-through-motion and low-perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include monitoring blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring.
Receive News & Ratings for Masimo Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Corp. and related companies with MarketBeat.com's FREE daily email newsletter.